MediVet-America today announced the opening of MediVet Lab Services in Lexington, Kentucky, to provide technical support for in-clinic animal stem cell procedures, regional and national Adipose Stem Cell Processing, Cryogenic Banking Services, Autologous Conditional Serum Processing, and Cell Counting Services for in-house stem cell treatments.
MediVet-America, the leading developer of stem cell regenerative therapy for adult animals suffering from osteoarthritis, hip dysplasia, ligament and cartilage injuries and other degenerative diseases, already provides equipment that allows veterinarians to perform Adipose Stem Cell procedures completely in-house. This new service will provide vets with access to a range of services, including processing of adipose tissue to extract adult stem cells.
MediVet Lab Services features a dedicated research and development department, a cell biologist and support staff. MediVet-America Managing Director Jeremy Delk envisions opening additional laboratories throughout the U.S., providing an interactive web site offering vet certification and a quality assurance/control program for cell counting and banking.
“MediVet-America is the only veterinary stem cell company that has developed its own technology and protocols,” said Delk. “We do not simply license the research of others. Our researchers and cell biologists ensure we stay on the forefront of this exciting technology. Furthermore, we are the only company offering a complete, one-stop range of affordable veterinary stem cell services for all veterinarians.”
MediVet-America pioneered the in-clinic animal stem cell therapy market. Since March 1, 2010, the company has signed agreements with more than 100 leading veterinarians across the U.S. and distributes the technology in eight countries worldwide. Veterinarians are seeing tremendous results; within weeks of a procedure, animals that had been lame, unable to climb stairs or jump up are walking, running and playing.
Delk added that with no processing/culture fee, MediVet Lab Services makes banked doses more affordable, with the ability to return large numbers of viable first generation cells.
“Our banked-dose recovery fee is as much as 35 percent less than other companies,” said Delk.